PTO/SB/01A (10-05)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)							
Title of Invention	IMIDAZOLE-BASED HMG-COA REDUCTASE INHIBITORS						
	named inventor(s), I/we declare that:						
	n is directed to:						
	The attached application, (and Preliminary Amendment, if applicable), or						
	Application No, filed on						
	as amended on (if applicable);						
I/we believe tha sought;	I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is						
	ved and understand the contents of the above-identified application, including the claims, as amended by any cifically referred to above;						
material to pate became availab	I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.						
	WARNING						
Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.							
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.							
Full Name of	nventor(s)						
Inventor 1	Mark Richard Bush						
Signature	Citizen of						
Inventor 2	Michael David Kaufman						
Signature	Citizen of						
X Additional i	nventors are being named on						

Approved for use through 07/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)						
Title of Invention	MIDAZOLE-BASED HMG-COA REDUCTASE INHIBITORS					
	amed inventor(s), I/we declare that:					
This declaration	n is directed to:					
	The attached application, (and Preliminary Amendment, if applicable), or					
	Application No, filed on					
·	as amended on (if applicable);					
I/we believe that sought;	I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is					
	ed and understand the contents of the above-identified application, including the claims, as amended by any cifically referred to above;					
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.						
	WARNING					
Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.						
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.						
Full Name of I	nventor(s)					
Inventor 3	Richard H Hutchings					
Signature	Citizen of					
Inventor 4	Robert Michael Kennedy					
Signature	Citizen of					
Additional in	ventors are being named on					



PTO/SB/01A (10-05)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.

de at a designation

APPLICATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)						
Title of I	MIDAZOLE-BASED HMG-COA REDUCTASE INHIBITORS					
	amed inventor(s), I/we declare that:					
This declaration						
	The attached application, (and Preliminary Amendment, if applicable), or					
	Application No, filed on					
	as amended on (if applicable);					
I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;						
	ed and understand the contents of the above-identified application, including the claims, as amended by any cifically referred to above;					
material to paten	e the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be tability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which be between the filing date of the prior application and the national or PCT International filing date of the art application.					
	WARNING					
Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available. All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.						
Full Name of I	nventor(s)					
Inventor 5	Scott D Larson					
Signature	Citizen of					
Inventor 6	Toni Jo Poel					
Signature	Citizen of					
X Additional in	ventors are being named on					

PTO/SB/01A (10-05)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN							
APPLICATION DATA SHEET (37 CFR 1.76)							
Title of Invention	IMIDAZOLE-BASED HMG-COA REDUCTASE INHIBITORS						
As the below n	amed inventor(s), I/we declare that:						
This declaratio	n is directed to:						
	The attached application, (and Preliminary Amendment, if applicable), or						
	Application No, filed on						
	as amended on (if applicable);						
I/we believe that sought;	I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is						
	red and understand the contents of the above-identified application, including the claims, as amended by any cifically referred to above;						
material to pater became availabl	I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.						
	WARNING						
Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.							
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.							
Full Name of I	nventor(s)						
Inventor 7	Yuntao Song						
Signature	Citizen of						
Inventor 8	Bharat K Trivedi						
Signature	Citizen of						
☐ Additional in	ventors are being named on						

Approved for use through 11/30/2005. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

		Applicat	ion Number			
		Filing Date				
POWER OF ATTORNEY			med Inventor		Mark Richard Bush	
and					IMIDAZOLE-BASED HMG-COA REDUCTASE INHIBITORS	
CORRESPONDE		Art Unit			TIEDOOTAGE IMMOTORIG	
INDICATION	ON FORM	Examine	r Name	<u> </u>		
•		Attorney	Docket Numb	ber	PC25862	
I hereby appoint:			-	-		
Practitioners at Customer Number 28880					•	
OR .						
Practitioners named below:						
	Name		Reg	gistratio	n Number	
					-	
•			 -			
as my/our attorney(s) or age	nt(s) to prosecute the application s Patent and Trademark Office co	identified	above, and to t	transact a	ıll	
# - .						
	the correspondence address for	the above	-ісепшес арріі	ication to		
The above-mentioned	Customer Number.					
OR						
The address associate	ed with Customer Number					
OR				•		
Firm or Individual Name						
Address						
Address						
City		s	tate	T	Zip	
Country					· I	
Telephone		Fa	х			
I am the:						
Applicant/Inventor.						
	the entire interest. See 37 CFR 3 FR 3.73(b) is enclosed. (Form P					
	SIGNATURE of App			f Record	<u> </u>	
Name	Mark Richard Bush					
Signature				•		
Date						
		he entire ir	terest or their i	represent	ative(s) are required. Submit multiple	
□ *Total of forms are submitted.						

PTO/SB/81(06-03)
Approved for use through 11/30/2005. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

		Applicati	ion Number	_		
		Filing Da	ite			
POWER OF	ATTORNEY	First Nan	ned Inventor	Mark Richard Bush		
and		Title		IMIDAZOLE-BASED HMG-COA REDUCTASE INHIBITORS		
CORRESPONDE		Art Unit	2.0	TESSO ASE WITH STORE		
INDICATION	JN FORM	Examine	r Name			
		Attorney	Docket Number	PC25862		
I hereby appoint:						
Practitioners at Custon	2888	0				
OR						
Practitioners named b		т	Di-A	and an Alexander		
: 	Name Name		Hegisti	ation Number		
i 						
as my/our attorney(s) or age	nt(s) to prosecute the application s Patent and Trademark Office o	n identified a	above, and to trans	act all		
	the correspondence address for			an to:		
	·	THE ALLOVE	пениней аррисан	on to.		
The above-mentioned	Customer Number.					
OR						
The address associate	ed with Customer Number					
OR						
П						
Firm or Individual Name						
Address						
Address						
City		St	tate	Zip		
Country						
Telephone		Fax	× T			
·	<u> </u>					
I am the: Applicant/Inventor.						
	the entire interest. See 37 CFR 3 FR 3.73(b) is enclosed. (Form P					
	SIGNATURE of App	olicant or	Assignee of Re	cord		
Name	Michael David Kaufman					
Signature						
Date						
NOTE: Signatures of all the inveforms if more than one signature		the entire in	terest or their repre	sentative(s) are required. Submit multiple		
□ *Total of forms are submitted.						

Approved for use through 11/30/2005. OMB 0651-0335
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

		Applicati	on Number			
		Filing Da	te			
POWER OF ATTORNEY			ned Inventor	Mark Richard Bush		
an		Title		IMIDAZOLE-BASED HMG-COA REDUCTASE INHIBITORS		
CORRESPONDE	NCE ADDRESS ON FORM	Art Unit				
INDICATION	Examine	r Name				
		Attorney	Docket Number	PC25862		
I hereby appoint:						
Practitioners at Custor	mer Number	2888	0			
OR	L					
Practitioners named b	elow:					
	Name		Registra	tion Number		
			-			
as my/our attorney(s) or age	nt(s) to prosecute the applications s Patent and Trademark Office o	n identified a	bove, and to transa	ct all		
	the correspondence address fo	r the above-	dentified application	1 10:		
The above-mentioned	Customer Number.					
OR	_					
The address associate	ed with Customer Number					
OR .						
[] Fi	· · · · · · · · · · · · · · · · · · ·					
Firm or Individual Name			•			
Address						
Address						
City		St	ate	Zip		
Country		•	•			
Telephone		. Fax	۲			
I am the:						
Applicant/Inventor.			•			
Assignee of record of Statement under 37 C	the entire interest. See 37 CFR FR 3.73(b) is enclosed. (Form F	3.71. PTO/SB/96).	•			
	SIGNATURE of Ap	plicant or	Assignee of Rec	ord		
Name	Richard H Hutchings					
Signature	·					
Date						
NOTE: Signatures of all the inve forms if more than one signature		the entire in	terest or their repres	entative(s) are required. Submit multiple		
*Total of forms are su	*Total of forms are submitted.					

Approved for use through 11/30/2005. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

		Applicat	tion Numb	er		
POWER OF ATTORNEY		Filing Da	ate			
		First Na	med Inven	itor	Mark Richard Bush	
and		Title			IMIDAZOLE-BASED HMG-COA REDUCTASE INHIBITORS	
	ENCE ADDRESS	Art Unit				
INDICATION	JN FORM	Examine	er Name			
		Attorney	Docket N	lumber	PC25862	
I hereby appoint:				_		
Practitioners at Customer Number 28880						
OR						
Practitioners named below:						
	Name			Registrati	on Number	
						
as my/our attorney(s) or age	ent(s) to prosecute the application is Patent and Trademark Office co	identified	above, and	d to transact	all	
	Please recognize or change the correspondence address for the above-identified application to:					
The above-mentioned	·	1110 00010	-luorumou .	арриосион	5 .	
OR	Customer number.					
	Γ-			٦		
The address associate	ed with Customer Number					
OR						
Firm or Individual Name						
_						
Address						
Address						
City		s	tate		Zip	
Country .		l s.				
Telephone	<u></u>	Fa	<u>×</u>			
I am the:						
Applicant/Inventor.						
	the entire interest. See 37 CFR 3 CFR 3.73(b) is enclosed. (Form P					
	SIGNATURE of App	olicant or	Assigne	e of Recor	ď	
Name	Robert Michael Kennedy					
Signature	I					
Date						
NOTE: Signatures of all the inveforms if more than one signature	entors or assignees of record of the is required, see below*.	he entire in	iterest or th	neir represer	ntative(s) are required. Submit multiple	
□ *Total of forms are submitted.						

Approved for use through 11/30/2005, OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

	The or roos, no persons are require	Applicat	ion Num	ber			
		Filing Da	ate		-		
POWER OF	ATTORNEY	First Na	med Inve	entor	Mark Richard Bush		
and		Title			IMIDAZOLE-BASED HMI REDUCTASE INHIBITOR		
	ENCE ADDRESS	Art Unit					
INDICATION	JN FORW	Examine	er Name				
		Attorney	Docket	Number	PC25862		
I hereby appoint:				_			
Practitioners at Custon	Practitioners at Customer Number 28880						
OR							
Practitioners named below:							
_	Name			Registrati	on Number	1	
					 	ł	
]	
						j	
as my/our attorney(s) or age business in the United State	ent(s) to prosecute the application s Patent and Trademark Office or	identified	above, a	nd to transact	all		
Please recognize or change the correspondence address for the above-identified application to:							
The above-mentioned Customer Number.							
OR							
The address associate	ed with Customer Number						
Firm or Individual Name							
Address							
Address							
City		S	tate		Zip		
Country							
Telephone		Fa	х			_	
I am the: Applicant/Inventor. Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).							
	SIGNATURE of App			ee of Recor	d		
Name	Scott D Larson						
Signature							
Date							
	entors or assignees of record of the is required, see below*.	he entire in	iterest or	their represer	ntative(s) are required. S	ubmit multiple	
□ *Total of forms are submitted.							

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

		Application Nu	nber				
		Filing Date					
POWER OF	First Named Inv	rentor	Mark Richard Bush				
an	Title		IMIDAZOLE-BASED HMG-COA REDUCTASE INHIBITORS				
CORRESPONDE		Art Unit					
INDICATION	ON FORIVI	Examiner Name)				
		Attorney Docke	t Number	PC25862			
I hereby appoint:							
Practitioners at Custor	stomer Number 28880						
OR OR							
Practitioners named below:							
	Name		Registra	ion Number	İ		
·					1		
as my/our attorney(s) or age	nt(s) to prosecute the applications Secure Trademark Office	on identified above,	and to transac	t all			
				· •			
	the correspondence address for	or the above-identilis	ей аррисацол	io: · .			
The above-mentioned	Customer Number.						
OR							
The address associate	ed with Customer Number		*				
OR							
Firm or							
· Individual Name							
Address							
Address				•			
City		State		Zip			
Country ·							
Telephone-		Fax					
I am the:				" " 			
Applicant/Inventor.							
	the entire interest. See 37 CFR FR 3.73(b) is enclosed. (Form						
	SIGNATURE of A	plicant or Assig	nee of Reco	rd			
Name	Toni Jo Poel	·					
Signature							
Date							
		the entire interest of	r their represe	ntative(s) are required. Submit multip	le		
_	□ *Total of forms are submitted.						

Approved for use through 11/30/2005. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

		Applicati	ion Numbe	er		_	
		Filing Da	ite				
POWER OF ATTORNEY		First Nar	med Invent	.or	Mark Richard Bush		
ar		Title			IMIDAZOLE-E REDUCTASE		
	ENCE ADDRESS	Art Unit					
INDICATE	INDICATION FORM						
1				umber	PC25862		
I hereby appoint: Practitioners at Custon	2888	30					
OR							
Practitioners named b	elow:						
	Name		F	Registrati	ion Number		
					· · · · · ·		
as my/our attorney(s) or age business in the United State	ent(s) to prosecute the applications and Trademark Office	on identified a	above, and nerewith.	to transact	all		
Please recognize or change the correspondence address for the above-identified application to:							
	·	Ji Hic abo	Iucininoc	ррпошо	J.		
OR	e-mentioned Customer Number.						
UH	· ·						
The address associate	ed with Customer Number						
OR				_			
Firm or Individual Name							
Address							
Address							
City		St	tate		Zip		
Country	·						
Telephone		Fax	×				
I am the:							
Applicant/Inventor.							
	the entire interest. See 37 CFR CFR 3.73(b) is enclosed. (Form I						
	SIGNATURE of Ap			of Recor	rd		
Name	Yuntao Song						
Signature							
Date			-				
NOTE: Signatures of all the inve		f the entire in	terest or the	eir represer	ntative(s) are r	required. Su	ıbmit multiple
forms if more than one signature	e is required, see below*.						
□ *Total of forms are submitted.							

PTO/SB/81(06-03)
Approved for use through 11/30/2005. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

		Applicat	on Numbe	r		
			ite			
POWER OF	ATTORNEY	First Na	ned Invent	or	Mark Richard Bush	
and					IMIDAZOLE-BASED HMG-COA REDUCTASE INHIBITORS	
	INCE ADDRESS	Art Unit				
INDICATION	JN FORM	Examine	r Name			
		Attorney	Docket N	ımber	PC25862	
I hereby appoint:						
Practitioners at Custon	mer Number	2888	0		·	
OR						
Practitioners named b	elow:					
•	Name			Registrati	on Number	
•						
as my/our attorney(s) or age business in the United State	nt(s) to prosecute the applications S Patent and Trademark Office o	n identified a	above, and nerewith.	to transact	all	
Please recognize or change	the correspondence address for	r the above-	identified a	pplication t	o:	
The above-mentioned						
OR		•				
The address associate	ed with Customer Number					
On .						
Firm or Individual Name						
Address						
Address				,		
City		S	ate		Zip	
Country						
Telephone	•	Fa	×		•	
I am the:						
Applicant/Inventor.						
Assignee of record of Statement under 37 C	the entire interest. See 37 CFR : FR 3.73(b) is enclosed. (Form F	3.71. <i>PTO/SB/96</i>).				
	SIGNATURE of App	plicant or	Assignee	of Reco	^r d	
Name	Bharat K Trivedi					
Signature						
Date						
NOTE: Signatures of all the inve forms if more than one signature	entors or assignees of record of e is required, see below*.	the entire in	terest or the	eir represer	ntative(s) are required. Submit multiple	
□ *Total of forms are submitted.						